Endothelial-Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary Hypertension.
CD44 variant isoform
endothelial–mesenchymal transition
pulmonary arterial hypertension
sulfasalazine
xCT
Journal
American journal of respiratory cell and molecular biology
ISSN: 1535-4989
Titre abrégé: Am J Respir Cell Mol Biol
Pays: United States
ID NLM: 8917225
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
pubmed:
22
3
2019
medline:
28
3
2020
entrez:
22
3
2019
Statut:
ppublish
Résumé
Pulmonary arterial hypertension (PAH) pathogenesis shares similarities with carcinogenesis. One CD44 variant (CD44v) isoform, CD44v8-10, binds to and stabilizes the cystine transporter subunit (xCT), producing reduced glutathione and thereby enhancing the antioxidant defense of cancer stem cells. Pharmacological inhibition of xCT by sulfasalazine suppresses tumor growth, survival, and resistance to chemotherapy. We investigated whether the CD44v-xCT axis contributes to PAH pathogenesis. CD44v was predominantly expressed on endothelial-to-mesenchymal transition (EndMT)-like cells in the neointimal layer of PAH affected pulmonary arterioles.
Identifiants
pubmed: 30897333
doi: 10.1165/rcmb.2018-0231OC
doi:
Substances chimiques
Cd44 protein, mouse
0
Hyaluronan Receptors
0
Protein Isoforms
0
Reactive Oxygen Species
0
Sulfasalazine
3XC8GUZ6CB
Glutathione
GAN16C9B8O
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
367-379Commentaires et corrections
Type : CommentIn